Margaret Anderson
Showing 1–15 of 18 transcripts.
- Milken Institute1h 1m
A Journey to the Cutting Edge of Bioscience: Cancer as a Case Study
Margaret Anderson, Greg Friberg, Douglas Lowy, Fouad Namouni, Ellen Sigal, Nikhil Wagle, Angie Wilson, Sebastian Hermelin
Advancing from a generalized approach to highly personalized medicine, oncology has achieved unprecedented five-year survival rates for metastatic melanoma and long-term remission in lung cancer through immunotherapy and combination strategies. Despite these clinical successes, the sector faces significant hurdles including low clinical trial enrollment in community settings, fragmented electronic health record data, and ethical barriers to information sharing. To overcome these obstacles, stakeholders are leveraging artificial intelligence, patient-centered initiatives like "Count Me In," and predictive modeling to integrate community biospecimens and accelerate the development of functional cures.
- Milken Institute57 min
Health Citizenship: The Nexus of Data, Technology and Research
Margaret Anderson, Stephanie Devaney, Eric Friedman, Joyce Tung, Bernard J. Tyson, Roni Zeiger
This panel introduces the concept of "health citizenship," a strategic shift toward a two-way dialogue between patients and providers that redefines healthcare delivery beyond episodic care. Featuring insights from leaders at Kaiser Permanente, 23andMe, and the All of Us Research Program, the discussion highlights how leveraging diverse data sources, mobile health technologies, and community-based interventions can improve equity and treatment outcomes. The event concludes by emphasizing the necessity of modernizing regulatory frameworks and adopting AI-driven, team-based models to sustain this transition toward proactive, personalized health management.
- Milken Institute1h 1m
What Does Brexit Mean for Health Care and Medical Research?
Aisling Burnand, Pierre Meulien, Isabelle Moulon, Margaret Anderson, Annalisa Jenkins
This panel outlines a paradigm shift in biomedical research where academia, industry, regulators, and patients collaborate through massive initiatives like the €5 billion Innovative Medicines Initiative to overcome historical silos and complex disease challenges. Key figures including Annalisa Jenkins of Dimension Therapeutics and Isabel Mugon of the European Medicines Agency highlighted how the externalization of innovation and early patient integration are accelerating drug development, even as Brexit risks to financial and human capital require new government support. The collective consensus emphasizes that while healthcare systems lag behind rapid scientific advances, the sector is moving toward a unified, data-driven ecosystem prioritizing real-world evidence and measurable patient outcomes over isolated achievements.
- Milken Institute1h 10m
Lunch Program | This Changes Everything: How Technology Is Revolutionizing Medicine
Margaret Anderson, Mike Milken, Jack Gilbert, Elizabeth Blackburn, Vadim Bachman, Nina Tandon, Juan Enriquez, Mike Cloughton
Based at the Milken Institute, Faster Cures convenes leading scientists like Dr. Elizabeth Blackburn and Juan Enriquez to advocate for a systemic overhaul of biomedical research that addresses the critical gap between 10,000 known diseases and the 500 treatments currently in development. The event highlights transformative breakthroughs in genomics, microbiome manipulation, and synthetic biology, demonstrating how technologies such as nanocytology and living implants are shifting medical paradigms toward early detection and regenerative solutions. By integrating public policy advocacy with these scientific advancements, the organization aims to optimize the research ecosystem and accelerate the delivery of cures for conditions ranging from cancer to neurodegenerative disorders.
- Milken Institute1h 14m
Sustaining the New 'Golden Age' of Medical Research
Margaret Anderson, Francis Collins, Kathy Giusti, Michael Milken, Kevin Yoder, Elias Zerhouni
At the 19th annual Milken Institute Global Conference, leaders including Kathy Hudson, Elias Zerhouni, and Francis Collins convened to address systemic inefficiencies in biomedical research while celebrating unprecedented therapeutic breakthroughs. The panelists emphasized that stagnant NIH funding and a 16% grant success rate threaten the scientific pipeline, yet initiatives like the Precision Medicine Initiative and Accelerating Medicine Partnerships are introducing parallel processing and open data models to accelerate cures. By reframing research as a national security priority and integrating artificial intelligence, these experts argue that coordinated public-private ecosystems can overcome current bottlenecks to deliver transformative medical advancements.
- Milken Institute56 min
Mental Health: A Global Challenge We Can't Ignore
Margaret Anderson, Olga Acosta Price, Pamela Collins, Paolo del Vecchio, Charles Ingoglia
This panel convened experts to address the global crisis where mental disorders cause over 8 million annual deaths and severely limit life expectancy due to systemic resource scarcity and stigma. Researchers and policymakers highlighted the shift toward neurodevelopmental and immunological models while stressing that 75% of children with needs remain untreated because of misaligned funding and fragmented care delivery. The discussion concluded with urgent calls for legislative action, including the proposed "Excellence in Mental Health Act," to mandate evidence-based standards and transition payment models toward value-driven outcomes.
- Milken Institute58 min
London Summit 2015 - Tech Rx: Harnessing Big Data to Cure Disease
Margaret Anderson, Mary Baker, Albert Bourla, Gianrico Farrugia, Nicole Mather, Nicola Perrin
Hosted by Margaret Anderson of Faster Cures, this session united stakeholders from the European Brain Council, Mayo Clinic, Pfizer, and the UK government to discuss leveraging big data for accelerating disease cures. Key speakers highlighted critical progress in utilizing real-world data for clinical decisions while underscoring persistent barriers regarding data quality, privacy regulations, and public trust. The collective outcome emphasized a strategic shift toward unified global data infrastructure and patient-centered outcomes to transform biomedical research from hypothesis generation into actionable, equitable therapies.
- Milken Institute1h 12m
Accelerating Medical Research: The Bipartisan Quest for Cures
Margaret Anderson, Bob Hugin, Francis Collins, Mike Milken, Sara Radcliffe, Joe Barton
Hosted by Faster Cures, the 18th Global Conference convened over 160 sessions to address the critical intersection of biomedical innovation and economic stability, featuring strategic insights from Bob Hugin, Mike Milken, and Francis Collins regarding the shrinking purchasing power of NIH funding and China's aggressive bioscience investments. Speakers highlighted the urgent need to revise legislative frameworks, such as the bipartisan 21st Century Cures initiative and dynamic scoring practices, to counter a 23% decline in federal research support that threatens U.S. leadership against global competitors. The event concluded with a unified call to action for sustained advocacy and targeted funding for young scientists to secure future breakthroughs in precision medicine and drug repurposing.
- Milken Institute1h 4m
Precision Medicine: Accelerating Treatments From Potential to Reality
Mike Milken, Margaret Anderson, Pradeep Khosla, Brian Drucker, Betsy Nabel, Sam Hoggud
Distinguished experts including Pradeep Khosla, Brian Drucker, and Sam Hogg convened to discuss the transformation of medicine into a collaborative, data-driven field where precision and artificial intelligence have replaced traditional research silos. Despite significant breakthroughs like the rapid development of Gleevec, panelists warned that underfunding, a lack of trained physician-scientists, and intense global competition threaten U.S. leadership in the bioscience sector. The group concluded that realizing this "golden age of medicine" requires an urgent Apollo-style initiative, multi-sector co-investment, and a cultural shift toward patient partnerships to secure global health preeminence.
- Milken Institute1h 3m
2014 London Summit - Collaborating to Fund Bioscience
Margaret Anne Craig, Steve Ford, David Loew, Mark Treherne, John Reed, Margaret Anderson
Industry leaders and UK government officials convened to address the critical friction of clinical trial attrition, highlighting exponential biotech growth in European hubs alongside the urgent need for new biomarkers to de-risk neurodegeneration research. Major pharmaceutical players like Roche and Sanofi are engaging in pre-competitive collaborations to pool data and reduce sample sizes, while academic institutions face pressure to shift from publishing-centric models toward translational commercialization. Simultaneously, patient advocacy groups and policymakers are advocating for consolidated funding strategies and digital tools to align European charitable efforts with US-scale initiatives and accelerate the development of disease-modifying therapies.
- Milken Institute1h 0m
Unlocking the Mysteries of the Brain
Margaret Anderson, Adam Ghazali, Alan Jones, Jennifer Bristar, Henry Markham, Mark Schnitzer
Driven by a stagnating global disease burden in neuroscience and the limitations of symptom-based diagnostics, major international initiatives from the U.S. and Europe are mobilizing billions in funding to transition the field toward large-scale, data-driven collaboration. These efforts aim to replace fragmented research with shared biological markers and emerging hybrid therapies, such as neuroplasticity software and deep brain stimulation, to address complex disorders like dementia and depression. Ultimately, this paradigm shift seeks to redefine neurological health as a dynamic spectrum while dismantling the silos and stigma that currently hinder effective treatment and public understanding.
- Milken Institute1h 1m
The Big Shift: Diversity as a Business Rationale
Pamela, Alexandra, Richard, Javier, Margaret Anderson
Credit Suisse panelists and executives detailed the launch of their "New Markets" business unit designed to target women, African-Americans, and the LGBT community, citing a $12 trillion combined investment opportunity that remains underserved by current financial services. Speakers highlighted the necessity of executive sponsorship and internal data showing these segments generate outperforming returns while emphasizing that authentic progress requires top-down cultural shifts rather than quota-based hiring mandates. The discussion further explored strategic approaches to mentorship, advocacy, and the evolving legal landscape driving Fortune 500 engagement with these historically marginalized demographics.
- Milken Institute47 min
The 2014 Atlanta Summit - - The Economic Burden of Chronic Disease: Preventing the Preventable
Ross DeVol, Margaret Anderson, Steve Bird, David Heber, Ken Thorpe
Milken Institute's Ross Duvall, Safeway's Steve Bird, UCLA's David Heber, and Emory's Ken Thorpe presented a unified analysis revealing that rising chronic disease prevalence, particularly in diabetes and stroke, is the primary driver of escalating healthcare costs despite controlled medical inflation. The panel highlighted successful private-sector interventions, such as Safeway's biometric wellness programs and social network strategies for obesity, which achieved significant cost reductions by targeting visceral fat and behavioral incentives rather than relying solely on traditional medical treatment. To scale these proven models, the speakers urged policymakers to reframe Medicare reform as a proactive health strategy, overcome Congressional Budget Office scoring constraints, and replace fee-for-service payment structures with value-based incentives that prioritize prevention and early disease management.
- Milken Institute54 min
MI Summit 2013 - London: Funding Medical Breakthroughs, Enriching Society
Ruxandra Draghia-Akli, Gary Nabel, Tim Peakman, Sir Mark Walport, Margaret Anderson
Hosted by Margaret Anderson, a panel of global health leaders including Sir Mark Walport and Gary Nabel convened to address the critical intersection of biomedical innovation and economic prosperity. The discussion highlighted transformative scientific breakthroughs such as universal flu vaccines and T-cell immunotherapy while outlining strategic frameworks like the European Innovative Medicines Initiative to bridge the gap between academic research and commercial application. Participants concluded that overcoming regulatory bottlenecks, scaling genomic sequencing, and fostering public-private collaboration are essential to transforming health data into tangible patient outcomes and national economic growth.
- Milken Institute1h 0m
Bioscience Discoveries That Will Blow Your Mind (updated)
Jack Andraka, David Baltimore, Francis Collins, Tejal Desai, Aydogan Ozcan, Margaret Anderson
Prominent figures including Jack Andraka, Tejal Desai, and NIH Director Francis Collins present breakthroughs in nanotechnology, genomics, and cellular engineering that promise to revolutionize early cancer detection, drug delivery, and precision medicine. While these innovations leverage falling sequencing costs, portable diagnostic devices, and adaptive sensor platforms to bridge the gap between molecular discovery and clinical treatment, panelists express deep concern over a 20% decline in real research funding. The collective discourse underscores an urgent need to redirect resources toward young innovators and high-risk projects to sustain the momentum of this biological renaissance.